1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Response Genetics, Inc

Response Genetics, Inc

RGDXQ
Response Genetics, IncUS flagOther OTC
0.00
USD
- -
- -
3,873.00Market Cap
Response Genetics, Inc
RGDXQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
TTM
FRC
2.55
2.21
1.11
0.7
0.68
1.2
1.18
0.7
0.2
0.26
- -
0.43
Revenue per Share
0.37
-0.84
-0.78
-0.93
-0.7
-0.26
-0.3
-0.29
-0.37
-0.43
- -
-0.37
Basic EPS, GAAP
0.11
0.83
-0.78
-0.72
-0.65
-0.39
-0.29
-0.34
-0.25
-0.36
- -
-0.34
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.31
-0.54
1.48
0.67
0.04
-0.18
-0.31
-0.02
0.15
0.89
2.42
-0.13
Book Value per Share
-0.31
-0.54
1.48
0.67
0.04
-0.18
-0.32
-0.03
0.13
0.8
1.41
-0.14
Tangible Book Value per Share
3
3
7
10
13
18
19
27
33
39
- -
39
Basic Weighted Avg Shares
7
6
8
7
9
21
23
19
7
10
18
17
Sales/Revenue/Turnover
27.65
-27.17
-70.58
-138.39
-103.75
-22.94
-25.09
-40.87
-128.02
-188.34
-118.5
-79.27
Operating Margin (%)
- -
- -
1
1
- -
- -
- -
- -
- -
1
2
1
Depreciation Expense
2
-1
-5
-9
-9
-5
-6
-8
-12
-17
-20
-14
Net Income, GAAP
0.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
27.86
-22.56
-64.87
-133.13
-103.03
-21.95
-25.18
-41.4
-187.19
-163.18
-111.88
-85.54
Profit Margin (%)
3
4
13
8
5
4
1
10
10
27
18
4
Working Capital
1
1
- -
- -
- -
- -
- -
- -
1
7
5
11
LT Debt
-3
-6
15
7
1
-3
-6
-1
6
35
33
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-86.32
-248.43
- -
- -
- -
- -
-82.57
-59.74
-808.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'14
Dec'14
Mar'15
ST Debt
- -
- -
- -
LT Borrowings
9
7
11
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
27
12
17

Working Capital

FRC

•

in mil. unless spec.
Sep'14
Dec'14
Mar'15
Total Current Assets
14
32
9
Cash, Cash Equivalents & STI
6
26
2
Accounts Receivable, Net
7
5
6
Inventories
- -
- -
- -
Total Current Liabilities
5
4
5
Payables & Accruals
3
4
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
1
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-172.21%
-134.07%
-4.45%
Free Cash Flow
42.3%
21.62%
6.52%
Net Income, GAAP
31.18%
34.69%
21.28%
Sales/Revenue/Turnover
22.5%
11.13%
76.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
6
5
4
5
7
2014
4
4
4
4
10
2015
4
- -
- -
- -
18

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
-0.03
-0.04
-0.08
-0.09
-0.37
2014
-0.09
-0.08
-0.09
-0.09
-0.43
2015
-0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
Cryosite Limited (CTE.AX)
SQI Diagnostics Inc. (SQD.V)
Euroespes, S.A. (EEP.MC)
Dirui Industrial Co.,Ltd. (300396.SZ)
MDxHealth S.A. (MDXH)
DNA Chip Research Inc. (2397.T)
Business
Response Genetics, Inc. is a Los Angeles-based life sciences company specializing in the research, development, marketing, and sale of pharmacogenomic tests and molecular diagnostic services primarily for cancer treatment. Its core offerings include pharmacogenomic tests; analysis of single biomarkers using polymerase chain reaction methods; global gene interrogation via microarray technology on paraffin or frozen tissue specimens; and clinical trial pharmacogenomic testing services for pharmaceutical companies. The company’s tests target multiple cancer types including lung, colon, gastric, breast, thyroid cancers, and melanoma. Founded in 1999 and headquartered in Los Angeles, California, Response Genetics operates primarily in the United States with efforts to expand international market access, including agreements to broaden distribution into regions such as Central America. Recent major developments include strategic expansion of its test portfolio and international distribution channels, continuing to focus on proprietary diagnostic tools that assist oncologists in therapy selection and cancer diagnosis. The company leverages its seasoned molecular diagnostic platforms and aims for growth through both organic initiatives and strategic alliances within the oncology diagnostics industry.

Company News

Company News APIChatGPT

  • defenseworld.net

    Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ)

  • defenseworld.net

    Reviewing Femasys (NASDAQ:FEMY) and Response Genetics (OTCMKTS:RGDXQ)